XML 94 R74.htm IDEA: XBRL DOCUMENT v3.23.1
Note 15 - Contingently Redeemable Noncontrolling Interests (Details Textual) - USD ($)
$ / shares in Units, $ in Thousands
1 Months Ended 12 Months Ended
Jun. 13, 2022
Nov. 12, 2020
Jun. 30, 2022
Dec. 31, 2020
Stock Issued During Period, Value, New Issues       $ 111,594
SEED Therapeutics Inc. [Member]        
Share Price (in dollars per share)   $ 7.5375    
Proceeds from Issuance Initial Public Offering   $ 50,000    
Research Collaboration and License Agreement with Eli Lilly [Member] | SEED Therapeutics Inc. [Member]        
Derivative Liability, Total $ 1,237     278
Series A-2 Preferred Shares [Member] | Research Collaboration and License Agreement with Eli Lilly [Member]        
Redeemable Noncontrolling Interest, Equity, Preferred, Fair Value 3,763     5,267
Series A-2 Preferred Shares [Member] | Research Collaboration and License Agreement with Eli Lilly [Member] | SEED Therapeutics Inc. [Member]        
Annual Return, Percentage   8.00%    
Number of Annual Redemption Installments   3    
Share Price (in dollars per share)   $ 0.50    
Temporary Equity, Stock Issued During Period, Value, New Issues       0
Convertible Instrument, Conversion Price (in dollars per share)   $ 2.5125    
Preferred Stock, Accretion of Redemption Discount       $ 0
Stock Issued During Period, Value, New Issues $ 5,000   $ 5,000  
Stock Issued During Period, Shares, New Issues (in shares) 1,990,000 1,990,000 1,990,000